Previous studies have shown that melanoma cells increase CPT1a-dependent fatty acid oxidation in response to treatment with MAPKi therapy, and inhibiting MAPK, glycolysis, and fatty acid oxidation together inhibits tumor cell growth in vitro and in vivo [23]. The gene discussed is CPT1A; the disease is melanoma.